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(DCE). METHODS: A discrete-event state-transition model was
developed to estimate the cost-effectiveness of all scenarios for all
patient groups. In addition, a discrete choice experiment (DCE)
was designed to establish patient preferences. The DCE incorpo-
rated three process attributes (duration of follow-up, frequency
and type of consult) and data were collected in a sample of 125
breast cancer patients. Patients had to complete all 18 choice sets
that were generated from the three attributes. RESULTS: The
modelling study revealed recommendations for follow-up in dif-
ferent age categories. Patients younger than 40 and patients with
unfavorable tumor characteristics (>3 lymph nodes, tumor size
>2 cm) can beneﬁt from a more intensive follow-up of ﬁve or
possibly ten years. Patients older than 40 but younger than 70
years old sometimes beneﬁt from a more intensive follow-up; e.g.
when younger than 50 and tumor size >2 cm. The DCE, however,
showed that patients chose maximum levels of follow-up inde-
pendent from age and their individual clinical risk proﬁle. Dura-
tion of follow-up and type of consult (either hospital visit or
telephone) weighted approximately 0.43 and 0.50 respectively.
The frequency of follow-up (either once or twice a year) was least
important (0.07). CONCLUSIONS: The model showed that
follow-up may be individualized according to risk proﬁle and
age. However, patients preferred long and intensive follow-up
strategies after breast cancer treatment. Taking into account indi-
vidual patient preferences it may be recommended to reduce the
frequency of follow-up to once a year. The service delivery by
nurse practioners is well appreciated and another means for
improving cost-effective follow-up.
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OBJECTIVES: In France, expensive innovative drugs are paid
by health insurance over and above per-case payments to hos-
pitals. Health authorities and pharmaceutical companies set a
ceiling price. Hospitals are encouraged to negotiate cheaper
prices and receive bonus payments equal to half of the differ-
ence. We assessed the impact of policy decisions about Taxanes
(Paclitaxel and Docetaxel) on the costs of breast cancer drugs,
both for health insurance and hospitals, on the turnover of
pharmaceutical companies and on the behaviours of these three
stakeholders. METHODS: We conducted 1) a retrospective
observational study to determine the resources allocated to che-
motherapy drugs in an actual clinical setting, and 2) a prospec-
tive study simulating stakeholders’ behaviours using clinical
evaluations of Taxanes, results of French epidemiological and
drug use studies and published drug prices. We assessed the
impact of 1) decreasing the ceiling price of Paclitaxel by 50%,
and 2) excluding Paclitaxel from the list of expensive innova-
tive drugs. RESULTS: Baseline economic data for drug use in
breast cancer are: €369 million expenditure for health insur-
ance; €0.73 million savings for hospitals, especially because of
the bonus payments; and €366 million turnover of pharmaceu-
tical companies. Decreasing the ceiling price of Paclitaxel has
an impact on hospitals who then might substitute Paclitaxel to
Docetaxel, but the manufacturer of Docetaxel can get the
market back by lowering actual price by 3%. The impact of
excluding Paclitaxel from the list of expensive innovative drugs
is small for health insurance but important for hospitals who
may then substitute Docetaxel to Paclitaxel. This increases
health insurance expenditures and health authorities must then
negotiate a lower ceiling price for Docetaxel. CONCLUSIONS:
Our study shows that policy decisions modify stakeholders’
behaviours, though not always as expected. This approach
could be used in the future for studying other expensive inno-
vative drugs.
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OBJECTIVES: A web-based survey was designed to conﬁrm time
and activities associated with mucositis management for
US-based radiation oncology staff treating HNC patients at dif-
ferent treatment stages. This study examined some of the respon-
dent and practice characteristics that were observed to be
associated with the mucositis management time. METHODS:
Respondents completing the survey were required to be either
licensed physicians (n = 50) treating at least 3 HNC patients per
month or RNs (n = 51) actively practicing in a radiation oncol-
ogy facility. The survey was designed after detailed interviews
with four physicians and nurses to identify key activities associ-
ated with mucositis management. Time associated with each task
was analyzed using descriptive statistics and summed to per-
patient per-treatment level. Nonparametric tests (Wilcoxon,
Spearman correlation) were used to explore the association
between respondent and practice characteristics and mucositis
management time by physician and nurse. RESULTS: Physicians
and nurses reported spending a median of 5.7 and 9.0 hours per
HNC patient, respectively, managing mucositis-related activities
from planning to post-treatment. Female physicians reported
spending more than male physicians (9.0 vs. 5.3 hours, p = 0.04),
and non-Caucasian (predominantly Asian) physicians reported
spending more time than Caucasian physicians (6.9 vs. 4.0 hours,
p = 0.03). Further, physician-reported time was signiﬁcantly
associated with total number of all patients treated per month
(r = 0.3, p = 0.04). Similar associations were not observed for
nurse respondents. Respondents’ years of practicing in radiation
oncology, number of HNC patients treated per month, total
number of HNC patients treated in previous two months, type of
facility respondents practicing at (private vs. community-based),
and facility HNC patient/clinician ratio were not associated with
the mucositis management time reported by respondents. CON-
CLUSIONS: The amount of time spent managing mucositis-
related activities for HNC patients receiving RT is substantial.
Physician-reported time varied substantially by gender and race
and was found to be associated with number of patients treated
per month.
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OBJECTIVES: Continuous suppression of the HER2+
(ErbB2+) receptor is an accepted treatment strategy for patients
with HER2+ MBC. However, consideration of the evidence base
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